What Is GHK-Cu?
GHK-Cu is a small copper-binding peptide found naturally in the human body. It is made from three amino acids and a copper ion. You are most likely to see it in skincare under the ingredient name copper tripeptide-1, although it is also promoted online for hair growth, wound healing and injectable “regeneration”.
The science is more uneven than those claims suggest. GHK-Cu has been studied for decades, and laboratory research gives plausible reasons why it could influence tissue repair. There are also small human studies involving topical products. However, large, modern clinical trials are lacking, many frequently repeated cosmetic results are difficult to trace to full peer-reviewed reports, and evidence from cells or animals cannot tell us whether injected GHK-Cu is safe or effective in people.
What does GHK-Cu stand for?
GHK describes the three amino acids in the peptide:
- G is glycine
- H is histidine
- K is lysine, using the standard one-letter amino-acid code
The Cu is copper. More precisely, it is usually a copper(II) ion held by the peptide.
GHK on its own is a peptide. GHK-Cu is the complex formed when that peptide binds copper. The names are sometimes used loosely online, but they are not chemically identical.
Is GHK-Cu a peptide?
Yes. GHK is a tripeptide, meaning it contains three amino acids linked together. It is much smaller than a protein and smaller than peptide medicines such as semaglutide or tirzepatide.
The copper ion does not turn it into a different class of molecule. It creates a metal-peptide complex. Histidine and other parts of the peptide help hold the copper in a coordinated structure.
That ability to bind copper matters because copper is involved in enzymes and processes needed for connective tissue, antioxidant defence and normal wound repair. Free copper can also take part in damaging chemical reactions. One proposed role of GHK is to carry or manage copper in a more controlled biological form.
Where does GHK-Cu come from?
GHK was first isolated from human plasma in the 1970s. Researchers later found it in other body fluids and identified its strong affinity for copper.
The peptide can also be released when larger proteins in the extracellular matrix are broken down. The extracellular matrix is the structural material around cells. It includes collagen and other components that give tissues strength and shape. Releasing a small signalling peptide during tissue damage would fit with the idea that GHK helps coordinate repair.
Published reviews often state that circulating GHK levels are higher in young adults and lower in older adults. The commonly quoted figures are about 200 nanograms per millilitre at age 20 and 80 nanograms per millilitre by age 60. These values come from older work and are widely repeated, but a lower blood level has not been shown to cause a specific feature of ageing or a particular disease. It is therefore too large a leap to say that replacing GHK reverses ageing.
Why is GHK-Cu blue?
GHK-Cu usually has a blue colour because of the copper(II) ion bound within the complex. Copper ions absorb and reflect visible light in ways that can give their compounds blue or blue-green colours.
Colour can be consistent with a copper complex, but it is not proof of identity, concentration, purity or sterility. A blue powder or liquid should not be assumed to contain correctly manufactured GHK-Cu simply because it looks as expected.
What does GHK-Cu appear to do?
Most of what researchers know comes from cells, isolated tissues and animals. Across these models, GHK or GHK-Cu has been reported to influence several parts of the repair process.
It can affect extracellular-matrix remodelling
Repair is not simply a matter of producing as much collagen as possible. Damaged matrix must be removed, new matrix must be made, and the two processes must remain balanced.
GHK-Cu has been reported to influence collagen, elastin, glycosaminoglycans, matrix metalloproteinases and their inhibitors. These findings support a role in remodelling rather than a simple one-way “collagen booster”. Much of this evidence comes from cell experiments and animal wounds.
It can change fibroblast behaviour
Fibroblasts are cells that help make and organise connective tissue. Laboratory studies have found changes in growth-factor signalling, collagen contraction and matrix-related activity after exposure to GHK or GHK-Cu.
One study used fibroblasts taken from people with chronic obstructive pulmonary disease. GHK changed gene-expression patterns and improved the cells' ability to contract and remodel collagen in the laboratory. This was an interesting disease-model result, not a clinical trial of GHK for lung disease.
It can influence inflammatory and antioxidant pathways
Cell and animal studies report changes in reactive oxygen species, antioxidant defences and inflammatory signals such as NF-kB, TNF-alpha and IL-6. These results help explain why GHK-Cu is studied in injury models.
They do not establish that a GHK-Cu product treats inflammation in people. A molecular pathway can be altered in a dish without producing a useful or safe clinical effect.
It can influence blood-vessel formation
New blood vessels help bring oxygen and nutrients to healing tissue. GHK-related peptides have shown angiogenic activity in experimental models, and GHK-Cu has been associated with growth factors involved in this process.
Again, more activity is not automatically better. Blood-vessel growth must be carefully controlled. This is one reason broad claims about “regeneration everywhere” are not a sound reading of the research.
What are the claimed benefits of GHK-Cu?
Common claims include smoother or firmer skin, fewer wrinkles, improved wound healing, reduced scarring, increased hair growth, less inflammation, faster recovery from injuries and even wider anti-ageing effects.
Those claims do not all have the same support. The clearest way to read the evidence is to separate the research stage from the marketing language.
| Claim or research area | What has actually been studied | Evidence position |
|---|---|---|
| Skin texture and visible ageing | Small topical human studies, older cosmetic reports, cell research | Some human evidence, but limited and not comparable with large drug trials |
| Wound repair | Extensive cell and animal work; a new controlled topical human trial is registered | Biologically plausible, but clinical effectiveness is not established |
| Hair growth | Follicle and formulation research; human studies often use multiple ingredients or procedures | GHK-Cu's individual effect is uncertain |
| Scars and acne marks | Mechanistic work involving collagen and growth signals | No strong clinical evidence that GHK-Cu treats acne or reliably removes scars |
| Inflammation and oxidative stress | Mainly cell and animal experiments | Preclinical evidence only for broad therapeutic claims |
| Lung, nerve, bone or internal-organ repair | Laboratory and animal models | Not established treatments in humans |
| Whole-body anti-ageing | Mechanistic arguments and animal observations | No evidence that GHK-Cu slows human ageing or extends life |
The word “benefit” should therefore be used carefully. A reported change in collagen production or gene expression is a research finding. It is not automatically a visible benefit, a medical treatment or evidence that a person should use the compound.
What does the human research show?
GHK-Cu is sometimes described as one of the best-studied regenerative peptides. That description is true only in a narrow sense. It has a long research history and a large mechanistic literature, but the human clinical evidence remains small and fragmented.
What the 2026 systematic review found
In August 2026, researchers published a systematic review of GHK-Cu in aesthetic medicine. A systematic review uses a planned search and selection method to collect the available studies rather than choosing individual papers informally.
The review included 20 studies. Eighteen were preclinical, meaning they used cells, isolated tissue or animals, and only two were randomised human trials. Randomisation uses chance to assign participants to comparison groups and helps reduce bias.
The authors found a consistent biological case for effects on the extracellular matrix, inflammation, blood-vessel formation and cell growth. The extracellular matrix is the structural network around cells and includes collagen and other supporting material. They also found that human evidence was limited by varied methods, formulations and delivery systems.
This review strengthens the account of why researchers remain interested in topical GHK-Cu. It also makes the evidence boundary clearer: 90% of the included studies were preclinical. It does not establish an injected or whole-body treatment and does not support transferring results from a topical formulation to an injectable product.
Cosmetic skin studies
Reviews describe several controlled studies of copper-peptide creams around the face, eyes and thighs. Frequently quoted reports include a 12-week facial study in 71 women, a 12-week eye-area study in 41 women and a thigh-skin study in 67 women. Improvements were reported in measures such as skin density, laxity, fine lines and collagen production.
These results are worth mentioning, but they need context. The underlying reports are old, some are cited as cosmetic or conference material rather than easily accessible full peer-reviewed clinical papers, and product formulations may contain more than GHK-Cu. This makes it difficult to independently examine randomisation, blinding, statistical analysis, ingredient concentration and the size of the effect.
The reasonable conclusion is that topical copper-peptide products have some encouraging human skin data. It is not reasonable to treat the headline percentages from these small studies as settled proof.
The laser-resurfacing trial
A published randomised trial gives a useful example of why positive and negative findings both matter. Thirteen people completed a study of GHK-Cu skincare after carbon-dioxide laser resurfacing.
Computer analysis and blinded assessors found no significant advantage for faster resolution of redness. Objective assessments also found no difference between groups in wrinkles or overall skin quality. People using the GHK-Cu products did report greater satisfaction with overall skin quality.
That result does not mean GHK-Cu never affects skin. It means this small trial did not confirm the main objective benefits being tested, even though the users preferred the treatment. A balanced guide should report both parts.
Does topical GHK-Cu work for skin?
Topical use is the most credible application because this is where most direct human experience exists. Even here, “works” needs an outcome attached to it.
There is some evidence that formulated copper-peptide products can affect measurements or appearance associated with photoaged skin. Laboratory studies also support effects on fibroblasts and matrix remodelling. However, the evidence does not tell us that every serum labelled copper tripeptide-1 will produce the same result.
The finished formulation matters. GHK-Cu is water-loving and does not automatically pass through the outer skin barrier in large amounts. Laboratory work using isolated human skin found that penetration depended on the skin layer and experimental conditions. Delivery systems and other ingredients may change how much reaches deeper tissue.
This also means a study of one finished cream cannot validate powders, homemade mixtures, injectable products or every retail serum that uses the same ingredient name.
Is GHK-Cu proven to heal wounds?
GHK-Cu has a substantial wound-repair research history. Rat wound chambers, mouse burn models and cell studies have reported changes in collagen, glycosaminoglycans, cell proliferation, blood-vessel formation and wound closure.
These models are useful for discovering mechanisms and deciding whether human trials are justified. They are not proof that a cosmetic serum should be put on an open wound or that injected GHK-Cu improves healing in people.
A randomised human study of topical GHK-Cu gel for small standardised skin wounds was registered in 2026. The planned comparison is GHK-Cu gel against a matching vehicle, applied to separate experimental wounds. At the time of this review, the study does not provide completed outcome data. Its existence shows that the clinical question is still being tested.
Open wounds, burns, surgical sites and chronic ulcers require appropriate medical care. A product sold for intact cosmetic skin should not be assumed to be sterile or suitable for damaged tissue.
Does GHK-Cu help hair growth?
GHK-Cu is commonly sold in scalp serums and promoted as a hair-growth peptide. The theory draws on its effects on fibroblasts, blood-vessel signals, tissue remodelling and hair-follicle biology.
Direct proof in people is weak. Some human scalp studies have reported improvements while using products or injected mixtures that contained copper tripeptide-1. However, those mixtures also contained other active ingredients, growth factors or procedures. Without a suitable GHK-Cu-only comparison, the result cannot be assigned to GHK-Cu.
For example, a large open-label pilot study used scalp injections containing copper tripeptide-1 alongside several growth factors and thymosin beta-4. Hair measures improved, but there was no placebo group and GHK-Cu was only one part of the formulation. A 2024 open-label scalp study similarly combined copper tripeptide-1 with a scrub and several other serum ingredients.
These studies show that GHK-Cu appears in experimental hair and scalp formulations. They do not establish that GHK-Cu alone regrows hair, how it compares with established treatments, or whether injection is justified.
Hair loss also has many causes, including androgenetic alopecia, autoimmune disease, nutritional deficiency, thyroid disease, medication effects and physical stress. A cosmetic peptide cannot substitute for identifying the cause.
Does GHK-Cu help acne or acne scars?
There is no strong clinical evidence that GHK-Cu treats acne. Acne involves blocked follicles, oil production, inflammation, bacteria and hormonal signals. General anti-inflammatory findings from cells do not establish an acne treatment.
Claims about acne scars are also ahead of the evidence. GHK-Cu's effects on fibroblasts and matrix remodelling make scar research plausible, but different scars need different approaches. Raised scars, depressed scars and post-inflammatory colour changes are not the same problem.
Applying a new cosmetic can also irritate acne-prone skin. Anyone with persistent or scarring acne is better served by a proper diagnosis and treatments with direct human evidence.
What about GHK-Cu for the brain, lungs, gut or injury recovery?
These are active research ideas, not established human uses.
GHK has produced interesting gene-expression and tissue effects in experimental lung models. GHK or GHK-Cu has also been studied in animal models involving cognition, bone, ligaments, liver, intestinal tissue and inflammatory injury.
The route from an interesting model to a useful medicine is long. Researchers still need to establish how the compound is absorbed and distributed, what exposure reaches the target tissue, whether the effect is reproducible, which people might benefit, and what unwanted effects appear over time.
No evidence currently supports presenting GHK-Cu as a general repair signal that safely finds and fixes damaged tissue throughout the human body.
How has GHK-Cu been administered in documented research?
Research has used several routes, but a recorded research method is not a recommendation for personal use.
| Research setting | How the compound was studied | What the design can tell us |
|---|---|---|
| Human cosmetic studies | Finished creams or skincare systems used over periods such as 8 to 12 weeks | Can examine the particular topical formulation, but not injections or raw powder |
| Human laser-resurfacing study | A GHK-Cu skincare regimen compared with a regimen without it for 12 weeks | Small randomised study with objective and patient-reported outcomes |
| Human scalp studies | Multi-ingredient topical regimens or intradermal mixtures | Cannot isolate the effect of GHK-Cu |
| Isolated human skin | An aqueous copper-tripeptide preparation applied to separated skin layers | Measures laboratory penetration, not visible benefit or clinical safety |
| Cell studies | GHK or GHK-Cu placed directly into cell culture at controlled concentrations | Explores mechanisms without human absorption or whole-body biology |
| Animal wound studies | Local preparations, wound-chamber exposure or specialised delivery systems | Helps test repair mechanisms, but does not establish a human treatment |
The published literature does not provide an approved injectable dose, cycle or protocol for GHK-Cu. Orentra therefore does not convert experimental concentrations into instructions for people.
Topical GHK-Cu compared with injected GHK-Cu
The route changes the question completely.
| Feature | Topical cosmetic product | Compounded or research-labelled injection |
|---|---|---|
| Main intended exposure | Local surface application, usually to intact skin | Systemic or deeper tissue exposure |
| Human experience | Limited cosmetic studies and commercial use | Very limited safety information for GHK-Cu itself |
| Product status | Usually regulated as a cosmetic if it makes cosmetic claims | Not an FDA-approved GHK-Cu medicine |
| Main uncertainty | Formulation, penetration, irritation and whether the claimed cosmetic effect is real | Sterility, identity, purity, aggregation, immune reactions, dose and whole-body effects |
| Can evidence be transferred between routes? | No | No |
An injectable product is not a stronger version of a serum. It creates different exposures and different risks. Evidence that a topical cosmetic appears tolerable cannot be used to establish the safety of injection.
What did Health Canada's 2026 peptide warning find?
In November 2026, Health Canada reported that laboratory testing had found Sphingomonas aquatilis/melonis bacteria in one injectable peptide product seized from a Canadian retailer. The retailer's inventory also included products labelled GHK-Cu as part of a multi-peptide blend. The agency did not say that every listed product or batch was contaminated.
This is evidence of a product-quality problem in an unauthorised supply chain, not a clinical trial of GHK-Cu. Contamination of an injectable product can cause serious infection. A label stating 'for research use only' does not establish sterility or suitability for human use. The advisory does not imply that authorised medicines or regulated clinical-trial supplies were affected.
Is GHK-Cu safe?
There is no single safety answer for every product and route.
Topical cosmetic products containing copper tripeptide-1 appear to have a history of use, and small studies generally describe acceptable tolerability. Possible problems can still include redness, itching, irritation or allergic contact reactions. A reaction may come from GHK-Cu or from another ingredient in the finished product.
Long-term, high-quality safety data are limited. There is also little evidence for use in pregnancy, breastfeeding, children, people with disorders of copper metabolism, or on broken and infected skin.
Injectable GHK-Cu has a much larger evidence gap. The FDA states that compounded injectable products containing GHK-Cu may pose an immunogenicity risk because peptides can aggregate or contain peptide-related impurities. The agency also says that human data are limited for assessing safety.
Immunogenicity means the immune system may recognise a substance or impurity and react to it. Sterility and endotoxin contamination add further risks for any unapproved injectable product. A label saying “research use only” does not resolve those risks and does not mean a material is suitable for use in people.
Can GHK-Cu cause cancer?
There is no good human evidence showing that GHK-Cu causes cancer. There is also not enough long-term clinical evidence to declare every route and exposure risk-free.
The concern usually comes from the fact that tissue repair can involve cell growth and new blood vessels. Those processes are also used by tumours. That overlap creates a question worth studying, but it does not prove that GHK-Cu initiates or accelerates cancer.
Some laboratory analyses have instead reported gene-expression patterns that appear unfavourable to cancer growth. These are early mechanistic findings, not evidence that GHK-Cu prevents or treats cancer.
People with cancer, a recent cancer history or an unexplained skin lesion should not use general peptide claims to make treatment decisions. GHK-Cu is not an approved cancer therapy.
Is GHK-Cu FDA approved?
No GHK-Cu medicine is FDA approved for skin ageing, wound healing, hair growth, injury recovery or systemic anti-ageing treatment.
GHK-Cu can appear in cosmetics as copper tripeptide-1. In the United States, cosmetic ingredients generally do not receive FDA premarket approval, apart from colour additives. A cosmetic product on sale is therefore not evidence that the FDA reviewed GHK-Cu as safe and effective for a medical use.
The compounding position is separate and can be confusing. In May 2026, FDA materials listed GHK-Cu for non-injectable routes in Category 1 of substances under evaluation for the 503A bulks list. That interim category is not approval and does not establish clinical effectiveness. Injectable GHK-Cu was excluded from that non-injectable nomination, and the FDA separately lists potential safety risks for compounded injectable GHK-Cu.
Regulatory lists can change. The route, intended use, claims, product type and jurisdiction all matter.
Does GHK-Cu work?
The fairest answer is that GHK-Cu clearly does things in experimental systems, may have useful topical cosmetic effects, and has not yet been clinically established for most claims made about it.
This is not the same as saying the peptide is fake. Its chemistry is real, it exists naturally, and researchers have repeatedly observed biological activity. The problem is the jump from those facts to confident promises about injections, hair regrowth, scar removal, whole-body repair or anti-ageing.
A well-designed trial could eventually support some of those uses. Until then, the level of confidence should match the evidence that exists now.
What would stronger evidence look like?
For topical skin claims, useful evidence would include larger randomised trials using a clearly defined GHK-Cu formulation, a matched vehicle, blinded assessment, objective measurements, published concentrations, complete adverse-event reporting and follow-up after treatment stops.
For hair growth, GHK-Cu would need to be tested alone against a vehicle and, ideally, against an established treatment. Researchers would need to report hair counts, shaft diameter, photographs assessed by blinded reviewers, different hair-loss diagnoses and longer follow-up.
For wound treatment, trials would need to define the wound type and compare time to closure, infection, scarring, pain and adverse events. Results from a small controlled skin wound cannot automatically be transferred to diabetic ulcers, burns or surgical wounds.
Injectable or systemic development would require early-phase studies of pharmacokinetics, dose exposure, immune reactions, organ effects and manufacturing quality before claims of clinical benefit could be assessed responsibly.
GHK-Cu in the wider peptide catalogue
GHK-Cu sits in an unusual position. Unlike many synthetic research peptides, its core peptide occurs naturally in people and its topical cosmetic history is well established. Unlike an approved peptide medicine, it does not have a modern clinical programme defining a finished product, dose, indication, contraindications and long-term safety.
That makes it a good example of why the word “peptide” tells you very little on its own. A natural molecule, a cosmetic ingredient, a laboratory reagent, a compounded preparation and an approved medicine are different things, even when they share a chemical name.
For the wider foundation, read What Are Peptides?. You can also see how Orentra evaluates research and browse the peptide guide catalogue.
Frequently asked questions
What is GHK-Cu peptide?
GHK-Cu is a complex formed from the tripeptide glycine-histidine-lysine and a copper(II) ion. It occurs naturally in the body and has been studied in tissue remodelling, skin and wound-repair research.
What does GHK-Cu stand for?
G, H and K are the amino-acid codes for glycine, histidine and lysine. Cu is the chemical symbol for copper.
Is GHK-Cu the same as copper tripeptide-1?
Copper tripeptide-1 is the cosmetic ingredient name commonly used for the GHK-Cu complex. A finished serum may contain many other ingredients, so the product is not the same thing as pure GHK-Cu research material.
Why is GHK-Cu blue?
The copper(II) ion gives the complex its characteristic blue colour. Colour alone does not verify identity, strength, purity or sterility.
What is GHK-Cu used for?
It is used mainly as an ingredient in cosmetic skin and scalp products. Researchers also study it in models of tissue remodelling and wound repair. It is not an FDA-approved medicine for those uses.
Does GHK-Cu increase collagen?
Cell, animal and small cosmetic studies report changes in collagen production or remodelling. This does not mean every GHK-Cu product produces a predictable increase in human skin collagen.
Does GHK-Cu tighten skin or reduce wrinkles?
Small and older topical studies report improvements in some signs of photoageing, but the clinical evidence is limited. One small randomised study after laser resurfacing found no objective advantage for wrinkles or overall skin quality, although patient satisfaction was higher.
Does GHK-Cu grow hair?
There is biological and formulation research, but no strong evidence that GHK-Cu alone reliably regrows human hair. Studies using multi-ingredient scalp products cannot isolate its effect.
Does GHK-Cu help acne scars?
Its role in matrix remodelling makes the question plausible, but strong clinical evidence for treating acne scars is lacking.
Is topical GHK-Cu the same as injectable GHK-Cu?
No. They create different exposures and risks. Limited topical cosmetic experience cannot establish the safety of injection.
Is GHK-Cu safe to inject?
There is no FDA-approved injectable GHK-Cu medicine and human safety data are limited. The FDA identifies potential immunogenicity risks for compounded injectable GHK-Cu due to aggregation and peptide-related impurities.
Is GHK-Cu FDA approved?
No GHK-Cu medicine is FDA approved. Its use in cosmetics is not drug approval. Non-injectable GHK-Cu was listed in 2026 as a bulk substance under evaluation for certain compounding, which is also not approval.
How long does GHK-Cu take to work?
There is no established answer across products and uses. Some topical studies assessed skin over 8 to 12 weeks, but that does not guarantee a visible result or provide a timetable for another formulation.
Is AHK-Cu the same as GHK-Cu?
No. Both are copper-binding tripeptide complexes, but they contain different amino-acid sequences. Research on one should not automatically be attributed to the other.
Can GHK-Cu be taken orally?
GHK-Cu is a small peptide, but oral absorption, stability and clinical effectiveness have not been established in an approved medicine. A capsule or supplement claim should not be treated as equivalent to topical research.
Sources
Primary research, registered-study information and current FDA materials are used to separate laboratory findings, animal evidence, limited human studies and regulatory status.
Original research identifying the tripeptide GHK in human serum.
Open source →Lane and colleagues: SPARC as a source of copper-binding angiogenic peptidesResearch examining SPARC-derived copper-binding peptides and experimental blood-vessel activity.
Open source →Maquart and colleagues: GHK-Cu and connective-tissue accumulation in rat woundsExperimental rat-wound research examining connective-tissue components after local GHK-Cu exposure.
Open source →McCormack and colleagues: copper tripeptide in a human fibroblast modelLaboratory study of copper tripeptide and matrix-related behaviour in human dermal fibroblasts.
Open source →Miller and colleagues: randomised GHK-Cu skincare study after laser resurfacingSmall randomised study reporting objective and patient-rated outcomes after carbon-dioxide laser resurfacing.
Open source →Pickart: the human tripeptide GHK and tissue remodellingReview of GHK research involving tissue remodelling, repair processes and reported cosmetic studies.
Open source →Hostynek and colleagues: human skin retention and penetration in vitroLaboratory research examining retention and penetration of copper tripeptide in isolated human skin.
Open source →Hostynek and colleagues: human skin penetration by skin layerLaboratory study assessing copper-tripeptide penetration through separated layers of isolated human skin.
Open source →Campbell and colleagues: GHK in a laboratory model of emphysema-related remodellingGene-expression and fibroblast research using an experimental model related to chronic obstructive pulmonary disease.
Open source →Wang and colleagues: GHK-Cu liposomes in mouse wound healingMouse burn-wound research using a specialised GHK-Cu liposomal preparation.
Open source →Pickart and colleagues: regenerative and protective actions of GHK-CuReview covering the mechanistic, animal and limited human literature associated with GHK-Cu.
Open source →Dou and colleagues: the potential of GHK as an anti-ageing peptideReview of experimental GHK research and questions that would need stronger clinical evidence.
Open source →Mokhtar and colleagues: systematic review of GHK-Cu in aesthetic medicineSystematic review of 20 studies, including 18 preclinical studies and two randomised human trials, showing a large translational gap between experimental findings and clinical evidence.
Open source →Kapoor and Shome: multi-ingredient intradermal hair formulation pilot studyOpen-label scalp-injection study of a formulation containing copper tripeptide-1 alongside several other ingredients.
Open source →Patel and colleagues: multi-ingredient scalp regimen studyOpen-label study using a scalp scrub and serum containing copper tripeptide-1 and several other ingredients.
Open source →ClinicalTrials.gov: topical GHK-Cu gel for acute skin wound healingRegistered controlled human study of a topical GHK-Cu gel for small standardised skin wounds, without completed outcome data at the time of review.
Open source →FDA: authority over cosmetics and the absence of routine premarket approvalFDA explanation of how cosmetics are regulated and why cosmetic marketing is not drug approval.
Open source →FDA: bulk substances under evaluation for 503A compounding, updated May 2026FDA interim list of nominated bulk substances under evaluation, including non-injectable GHK-Cu in Category 1 at the time of review.
Open source →FDA: safety concerns for certain compounded bulk drug substancesFDA information identifying potential immunogenicity concerns and limited human safety data for compounded injectable GHK-Cu.
Open source →Last reviewed: 17 November 2026.